Logo

Tonix Entered into a Sponsored Research Agreement with Boston Children's Hospital to Study TNX-1500 for the Prevention of Graft-Versus-Host Disease in Animals

Share this

Tonix Entered into a Sponsored Research Agreement with Boston Children's Hospital to Study TNX-1500 for the Prevention of Graft-Versus-Host Disease in Animals

Shots:

  • Tonix & Boston Children's Hospital collaborated to study TNX-1500 (Fc-modified anti-CD40L mAb) in GvHD after HCT in animals
  • The primary objective of the preclinical research is to study the activity of TNX-1500 administered prophylactically to modify GvHD progression after HCT & support an IND application for human studies. The P-I study of TNX-1500 is expected to be initiated in H1’23
  • In animal studies, TNX-1500 showed activity in preventing organ rejection & was well tolerated in non-human primates. Non-human primate models of cardiac & kidney allograft transplantation successfully and safely prevented pathologic alloimmunity by blocking CD40L with TNX-1500 monotx. without clinical thrombosis

Ref: Tonix Image: Tonix

Click here to­ read the full press release 

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions